CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease

Hepatology

Volumn 38, Issue 2, 2003, Pages 428-435

  Emery, Maurice G ^a   Fisher, Jeannine M ^a   Chien, Jenny Y ^a   Kharasch, Evan D ^a   Dellinger, E Patchen ^b   Kowdley, Kris V ^a   Thummel, Kenneth E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORZOXAZONE; CYTOCHROME P450 2E1;

ALCOHOLISM; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME INDUCTION; FATTY LIVER; FEMALE; GASTROPLASTY; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; MALE; MORBID OBESITY; MORBIDITY; NONALCOHOLIC FATTY LIVER DISEASE; PRIORITY JOURNAL; WEIGHT REDUCTION;

EID: 0041764982     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50342     Document Type: Article

References (30)

1. Lieber C. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 1997;77:517-544.
2. Raucy JL, Lasker JM, Kraner JC, Salazar DE, Lieber CS, Corcoran GB. Induction of cytochrome P450IIE1 in the obese overfed rat. Mol Pharmacol 1991;39:275-280.
3. Wong BK, Ernest U S-W, Corcoran GB. An overfed rat model that reproduces acetaminophen disposition in obese humans. Drug Metab Dispos 1986;14:674-679.
4. Corcoran GB, Wong BK. Obesity as a risk factor in drug-induced organ injury: increased liver and kidney damage by acetaminophen in the obese overfed rat. J Pharmacol Exp Ther 1987;241:921-927.
5. Raucy J, Lasker J, Lieber C, Black M. Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys 1989;271:270-283.
6. Nelson S. Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin Liver Dis 1990;10:267-278.
7. Touloukian J, Kaplowitz N. Halothane-induced hepatic disease. Semin Liver Dis 1981;1:134-142.
8. Madan A, Parkinson A. Characterization of the NADPH-dependent covalent binding of [14C]halothane to human liver microsomes: a role for cytochrome P4502E1 at low substrate concentrations. Drug Metab Dispos 1996;24:1307-1313.
9. Spracklin DK, Hankins DC, Fisher JM, Thummel KE, Kharasch ED. Cytochrome P4502E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J Pharmacol Exp Ther 1997;281:400-411.
10. Kharasch ED, Hankins D, Mautz D, Thummel KE. Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet 1996;347:1367-1371.
11. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
12. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
13. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P4502E1 is increased in patients with nonalcoholic steatohepatitis. HEPATOLOGY 1998;27:128-133.
14. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000;105:1067-1075.
15. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001;281:G1135-1139.
16. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1 [published erratum appears in Chem Res Toxicol 1991;4:389]. Chem Res Toxicol 1990;3:566-573.
17. Yamazaki H, Guo Z, Guengerich FP. Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation. Drug Metab Dispos 1995;23:438-440.
18. Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. Clin Pharmacol Ther 1993;53:643-650.
19. Kharasch ED, Hankins DC, Baxter PJ, Thummel KE. Single-dose disulfiram does not inhibit CYP2A6 activity. Clin Pharmacol Ther 1998;64:39-45.
20. Kharasch ED, Hankins DC, Jubert C, Thummel KE, Taraday JK. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1. Drug Metab Dispos 1999;27:717-723.
21. O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994;56:359-367.
22. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 1999;94:2467-2474.
23. Semmes RL, Shen DD. Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins. Pharm Res 1990;7:461-467.
24. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, Inc., 1982.
25. Barr RG, Nathan DM, Meigs JB, Singer DE. Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann Intern Med 2002;137:263-272.
26. Ranlov I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion 1990;47:208-214.
27. Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, Norris HT, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990;85:1349-1355.
28. Song BJ, Veech RL, Saenger P. Cytochrome P450IIE1 is elevated in lymphocytes from poorly controlled insulin-dependent diabetics. J Clin Endocrinol Metab 1990;71:1036-1040.
29. Woodcroft KJ, Hafner MS, Novak RF. Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. HEPATOLOGY 2002;35:263-273.
30. Laethem RM, Balazy M, Falck JR, Laethem CL, Koop DR. Formation of 19(S)-, 19(R)-, and 18(R)-hydroxyeicosatetraenoic acids by alcohol-inducible cytochrome P450 2E1. J Biol Chem 1993;268:12912-12918.